biopharmatips

The biopharma industry depends on change to grow in an environment that instantaneously demands higher quality, lower costs, and higher productivity. In upstream process development , biological materials are either acquired from outside or injected and bred in culture, under regulated conditions, to produce products. On the other hand, in downstream process development , the products are collected, purified, tested, and packaged. Different forms of biopharmaceutical process development involve technicians to wisely control the environment in which the cells grow.  If the product is to be used as a drug, biomanufacturing experts must work in places where current Good Manufacturing Practices (cGMP) are followed strictly. The progress witnessed in the industry has been remarkable, but the refined exterior of bioprocessing hides an interior of despair that cries under the burden of current demands. The rise in production achieved previously have been a result of ...

Biopharmaceutical is one of the most elegant and sophisticated achievements of modern science. The large, composite structures of these drugs look extraordinary in the 3-D modeling systems. Additionally, they also perform their tasks incredibly well, offering high value with fewer side effects. Today, various multinational pharmaceutical firms are slowly moving to biopharma on a large scale. However, with this comes several challenges. Considering the growth the industry has seen and the intricacies of biopharma, it is not surprising that major changes are needed to equip laboratories and operations in biopharma. Here are some of the major challenges that the biopharmaceutical Process Development industry is facing right now: Some of the leading nations that produce biopharmaceutical drugs lack research components and best manufacturing practices. Pharma firms must be built in a way that they are equipped with the best operational facilities. Cost pressure is expected t...

In today’s competitive pharmaceutical market, a good product strategy and careful planning are vital to succeed. Pharma companies are competing on all fronts to develop innovative products to gain an upper hand in the market. Often these products fail to secure an advantage and end up being just another high cost centre for the company.  Thousands of clinical studie are being carried out as we speak, but only a few drugs get approval. In other words, the success rate of drugs under experiment making it to the shelves of a drug store or your medicine cabinet is quite low. This low success rate puts a lot of pressure on firms to keep a large set of products in the pipeline, thus increasing demands on process development groups to lower time-to-market and time-to-clinic. Additionally, the recently approved proteins are monoclonal antibodies that will need lifetime doses 10-100 times bigger than various recombinant protein drugs.  Drug process development is not ...